Related Experiment Video

Updated: Dec 5, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

496

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia

Heather C Murray1, Anoop K Enjeti2,3,4, Richard G S Kahl1

  • 1Cancer Research Program, Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, 2308, Australia.

Leukemia
|October 17, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

632
Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
08:38

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery

Published on: October 4, 2018

21.6K

Related Experiment Videos

Last Updated: Dec 5, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

496
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

632
Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
08:38

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery

Published on: October 4, 2018

21.6K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K

Articles linked to this work by shared authors, journal, and citation graph.

A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years.

Blood·2026

Multi-omics integration reveals vaccine-specific molecular signatures and temporal dynamics of COVID-19 immune responses.

Frontiers in immunology·2026

Machine learning and computational approaches to model therapeutic response and resistance in diffuse midline glioma.

Journal of neuro-oncology·2026

Sperm Proteomics and Phosphoproteomics: High-Throughput Methods Tailored to Gain Insight into Sperm Cell Signaling Pathways.

Methods in molecular biology (Clifton, N.J.)·2026

Infection risk in myelodysplastic syndromes is dynamic and immune driven.

Blood advances·2026

Cellular architecture and stage-specific germ-cell dynamics of the koala seminiferous epithelium.

Reproduction (Cambridge, England)·2026

Predicting long-term survival in primary myelofibrosis.

Leukemia·2026

Targeting the mitochondrial complex I subunit NDUFS2 potentiates FLT3 inhibition in acute myeloid leukaemia with FLT3 internal tandem duplication.

Leukemia·2026

Targeting the eIF4F translation initiation complex disrupts BCR::ABL1 translation and overcomes drug resistance in CML.

Leukemia·2026

Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms.

Leukemia·2026

Inhibition of PHB2/PINK1-mediated mitophagy potentiates venetoclax activity in acute myeloid leukemia.

Leukemia·2026

Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies.

Leukemia·2026

Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC.

JTO clinical and research reports·2026

Correction: GOLPH3 inhibits glioma cell apoptosis through the JNK signaling pathway.

Frontiers in genetics·2026

Application of Dual-Targeting Carbon Dot Nanozymes in Improving Hypoxia and Enhancing Small Interfering RNA-Mediated Gene Silencing for Hepatocellular Carcinoma.

Biomaterials research·2026

First demonstration of benzosultam CRBN ligand-mediated PROTACs for BTK and BRD4 degradation.

RSC medicinal chemistry·2026

Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.

Materials today. Bio·2026

Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us